Alvotech 6-K: UK court rejects injunction on AVT06 manufacturing

Rhea-AI Filing Summary

Alvotech furnished a Form 6-K noting that a justice of the UK High Court rejected an injunction request from Regeneron Pharmaceuticals, joined by Bayer, relating to manufacturing activities at Alvotech’s UK contract manufacturing organization for its Eylea biosimilar candidate, AVT06. The company attached a press release as Exhibit 99.1.

The Form 6-K, excluding Exhibit 99.1, is incorporated by reference into Alvotech’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), its Form F-3ASR (File No. 333-289006), and its Form S-8 (File No. 333-266881). Exhibit 99.1 is furnished, not filed.

Insights

Biopharma legal and regulatory analyst

UK judge rejected an injunction tied to AVT06 manufacturing.

The filing states a UK High Court justice rejected an injunction request concerning Alvotech’s CMO manufacturing for AVT06, an Eylea biosimilar candidate. This indicates the requested interim restriction was not granted, based on the excerpt.

The company furnished a press release as Exhibit 99.1, while the rest of the report is incorporated by reference into multiple registration statements. Cash-flow effects or commercial timing are not addressed in the excerpt.

The legal posture can evolve through subsequent proceedings. Any practical impact would depend on future court actions or regulatory milestones; the excerpt provides no additional dates beyond November 10, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ALVO report in its latest Form 6-K?

Alvotech reported that a justice of the UK High Court rejected an injunction request related to manufacturing activities for its AVT06 Eylea biosimilar at a UK CMO.

Which product was involved in the court decision for ALVO?

The decision relates to AVT06, Alvotech’s biosimilar candidate to Eylea.

Who sought the injunction mentioned by ALVO?

Regeneron Pharmaceuticals sought the injunction and was joined by Bayer.

What is included as Exhibit 99.1 in ALVO’s 6-K?

A press release dated November 10, 2025, which is furnished and not filed.

Is the 6-K incorporated by reference into ALVO’s registration statements?

Yes. The 6-K, excluding Exhibit 99.1, is incorporated by reference into Alvotech’s Forms F-3, F-3ASR, and S-8 listed in the filing.

Does ALVO’s filing describe any financial terms or proceeds?

No. The excerpt focuses on the court decision and incorporation-by-reference details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 05:12 PM EST Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-41421

Alvotech
(Translation of registrant's name into English)

9, Rue de Bitbourg,
L-1273 Luxembourg,
Grand Duchy of Luxembourg
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Incorporation by Reference

This Report on Form 6-K (this “Report”) of Alvotech (the “Company”) excluding Exhibit 99.1 attached hereto, shall be deemed to be incorporated by reference into the Company’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), the Company’s registration statement on Form F-3ASR (File No. 333-289006), and the Company’s registration statement on Form S-8 (File No. 333-266881) and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit 99.1 to this Report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Press Releases

On November 10, 2025, Alvotech issued a Press Release announcing that a justice of the UK High Court rejected an injunction request from Regeneron Pharmaceuticals, joined by Bayer, in relation to manufacturing activities at Alvotech’s CMO in the UK for Alvotech’s biosimilar to Eylea (AVT06). A copy of the Press Release is furnished herewith as exhibit 99.1.

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated November 10, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Alvotech
		(Registrant)
Date: November 10, 2025		/s/ Tanya Zharov
		Tanya Zharov
		General Counsel